Search

Displaying results 3381 - 3390 of 10000 in total
  1. Drug

    LY2275796

    go.drugbank.com/drugs/DB05165
    Investigational

    LY2275796 is a second-generation antisense anti-cancer drug candidate for clinical development. LY2275796 targets eukaryotic initiation factor- 4E (eIF-4E), a protein involved in the translation of key growth and survival factors that dr...

  2. Drug

    Besifovir dipivoxil

    go.drugbank.com/drugs/DB05020
    Investigational

    Besifovir dipivoxil is believed to inhibit viral proliferation by interrupting the replicating machinery of the virus. … The HBV polymerase is the enzyme that catalyzes the production of new RNA from the existing strand of RNA.

  3. Drug

    Ulotaront

    go.drugbank.com/drugs/DB15665
    Investigational

    Unlike other drugs used for this condition, SEP-363856 does not bind to the dopamine D2 receptors, but exerts actions on the trace amine–associated receptor 1 (TAAR1) and 5-hydroxytryptamine type 1A (5 … [A193506] SEP-363856 was developed by Sunovion pharmaceuticals.

  4. Drug

    AZD 3355

    go.drugbank.com/drugs/DB05404
    Investigational

    It is developed by AstraZeneca and is currently in phase I/II trials.

  5. Drug

    Mebanazine

    go.drugbank.com/drugs/DB09248
    ApprovedWithdrawn

    It was used in the past as an antidepressant in the 1960s, but has since been discontinued because of its hepatotoxic potential.

  6. Drug

    IPH 1101

    go.drugbank.com/drugs/DB05754
    Experimental

    IPH 1101 is a chemically-synthesized structural analog of non-conventional bacterial phosphoantigens which specifically activate the Vγ9Vδ2 T cell subset.

  7. Drug

    Typhoid Vaccine Live

    go.drugbank.com/drugs/DB11050
    ApprovedInvestigational

    The vaccine prevents the development of typhoid fever, an acute, febrile enteric disease caused by *Salmonella typhi* by inducing a local immune response in the intestinal tract.

  8. Drug

    Lovotibeglogene autotemcel

    go.drugbank.com/drugs/DB18680
    ApprovedInvestigational

    [A262736,L49256] On December 8, 2023, lovotibeglogene autotemcel was approved by the FDA under the brand name Lyfgenia for the treatment of sickle cell disease (SCD) in patients ages 12 and older who … exagamglogene autotemcel] (Casgevy), another gene therapy, with the two treatments comprising the first cell-based gene therapies for the treatment of SCD in patients 12 years and older to be approved by

  9. Drug

    Carbenoxolone

    go.drugbank.com/drugs/DB02329
    Experimental

    Antidiuretic side effects are frequent, but otherwise the drug is low in toxicity. [PubChem]

  10. Drug

    Gambir

    go.drugbank.com/drugs/DB14298
    Investigational

    Gambir is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.